Alzamend Neuro Bilan de santé

Santé financière contrôle des critères 3/6

Alzamend Neuro possède un total de capitaux propres de $-1.2M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $1.7M et de $2.9M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$1.19m
Fonds propres	-US$1.21m
Total du passif	US$2.88m
Total des actifs	US$1.67m

Mises à jour récentes de la santé financière

Recent updates

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Oct 05

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Sep 29

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Jul 18

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 18

Alzamend Neuro closes $14.4M IPO

Jun 17

Analyse de la situation financière

Passif à court terme: ALZN a des fonds propres négatifs, ce qui est une situation plus grave que des actifs à court terme ne couvrant pas les passifs à court terme.

Passif à long terme: ALZN a des capitaux propres négatifs, ce qui est une situation plus grave que des actifs à court terme ne couvrant pas les passifs à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: ALZN est sans dette.

Réduire la dette: ALZN a des capitaux propres négatifs, nous n'avons donc pas besoin de vérifier si sa dette a diminué au fil du temps.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ALZN dispose d'une piste de trésorerie suffisante pour 2 mois sur la base du dernier rapport flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Prévisions de trésorerie: ALZN devrait disposer d'une marge de trésorerie suffisante pour 2 mois sur la base des estimations de flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Alzamend Neuro Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Alzamend Neuro, Inc. announced delayed annual 10-K filing

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

Alzamend Neuro, Inc. announced delayed 10-Q filing

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Recent updates

Alzamend Neuro, Inc. Announces Full Data Set from Its Nonclinical Study: Comparing Brain and Plasma Lithium Carbonate in Alzheimer's Transgenic Mice

Alzamend Neuro, Inc. Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Alzamend Neuro, Inc. has filed a Follow-on Equity Offering in the amount of $6.5 million.

Alzamend Neuro, Inc. announced delayed annual 10-K filing

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding

Alzamend Neuro, Inc. has completed a Follow-on Equity Offering in the amount of $1.3 million.

Alzamend Neuro, Inc., Annual General Meeting, May 13, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

Alzamend Neuro, Inc., Annual General Meeting, Apr 30, 2024

Alzamend Neuro, Inc. announced delayed 10-Q filing

Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman

Price target decreased by 67% to US$20.00

New major risk - Revenue and earnings growth

Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients

Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001

New major risk - Market cap size

New major risk - Share price stability

Alzamend Neuro, Inc. Submits Investigational New Drug Application for A Phase IIA Clinical Trial in Major Depressive Disorder Patients of Its Next-Generation Lithium Therapeutic Drug Candidate AL001

Price target increased by 58% to US$6.50

Alzamend Neuro, Inc Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

Alzamend Neuro Receives Non-Compliance Notice From Nasdaq

Alzamend Neuro Receives Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

New major risk - Negative shareholders equity

Alzamend Neuro Receives Notification from Nasdaq Regarding Not Eligible for Second 180 Day Compliance Period

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001

Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001

Price target decreased by 41% to US$4.13

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$7.25

High number of new and inexperienced directors

Price target decreased to US$7.25

Alzamend Neuro, Inc. Receives FDA "Study May Proceed" Letter for Phase I/IIa Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (Alzn002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate

Alzamend Neuro Inc. Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’S Subjects

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Alzamend Neuro, Inc. Submits Ind Application for Phase I/Iia Trial for an Immunotherapy (Alzn002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Price target increased to US$15.00

Alzamend Neuro, Inc. Announces CFO Changes

Alzamend Neuro Receives Positive Pre-Ind Response from Fda for Al001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Alzamend Neuro Receives Non-Compliance Notice from Nasdaq

Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro, Inc. Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

No independent directors

Alzamend Neuro, Inc. Announces Appointment of Terri Hunter to Its Scientific Advisory Board

Alzamend Neuro Announces Full Data Set from Phase 1 First-In-Human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’S

Alzamend Neuro Announces Positive Topline Data from Phase 1 First-In-Human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’s

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Director recently sold US$57k worth of stock

Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease

Alzamend Neuro Receives Positive Results for Al002 in GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease

Alzamend Neuro Submits IND Application for Al001 for Dementia Related to Alzheimer’s Disease

Alzamend Neuro closes $14.4M IPO

Alzamend Neuro, Inc. has completed an IPO in the amount of $12.5 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines